MedChemExpress MCE - Products
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use.
| Product | Description | |
|---|---|---|
| ISRIB (trans-isomer) | ISRIB (trans-isomer) is a potent inhibitor of PERK with an IC50 of 5 nM. ISRIB potently reverses the effects of eIF2α phosphorylation (IC50=5 nM). Uses: Scientific research. Category: Signaling pathways. CAS No. 1597403-47-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 250 mg. Product ID: HY-12495. |  |
| IST5-002 | IST5-002, a potent Stat5a/b inhibitor, selectively inhibits transcriptional activity of Stat5a/b (IC50s: 1.5 μM for Stat5a, 3.5 μM for Stat5b). IST5-002 inducs cell apoptotic and death of prostate cancer cells and chronic myeloid leukemia (CML) cells. IST5-002 can be used in the research of prostate cancer and chronic myeloid leukemia (CML)[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: N6-Benzyladenosine-5'-phosphate. CAS No. 13484-66-7. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg. Product ID: HY-19527. | |
| Istaroxime hydrochloride | Istaroxime hydrochloride is a Na+/K+-ATPase inhibitor (IC50=0.11 μM) and a sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA 2) activator. Uses: Scientific research. Category: Signaling pathways. Alternative Names: PST2744 hydrochloride. CAS No. 374559-48-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15718A. | |
| Istiratumab | Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers[1][2][3]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: MM 141; MM-005. CAS No. 1509928-04-4. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99672. | |
| Istradefylline | Istradefylline is a very potent, selective and orally active adenosine A2A receptor antagonist with Ki of 2.2 nM in experimental models of Parkinson's disease. Uses: Scientific research. Category: Signaling pathways. Alternative Names: KW-6002. CAS No. 155270-99-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 200 mg; 500 mg. Product ID: HY-10888. | |
| ISX-1 | ISX-1 is an isoxazole. ISX-1 has anti-adipogenic and pro-osteogenic activities. ISX-1 can be used for the research of osteopenia and osteoporosis[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 909207-35-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-113790. | |
| ISX-9 | ISX-9 (Isoxazole 9) is a potent inducer of adult neural stem cell differentiation. ISX-9 activates Ca2+ influx through both voltage-gated Ca2+ channels and NMDA receptors and increases neuroD expression. ISX-9 also induces cardiomyogenic differentiation of Notch-activated epicardium-derived cells (NECs)[1][2][3]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: Isoxazole 9. CAS No. 832115-62-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 250 mg; 500 mg. Product ID: HY-12323. | |
| IT1t dihydrochloride | IT1t dihydrochloride is a potent CXCR4 antagonist; inhibits CXCL12/CXCR4 interaction with an IC50 of 2.1 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 1092776-63-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-101458A. | |
| IT-901 | IT-901 is an orally active and potent NF-κB subunit c-Rel inhibitor with an IC50 of 0.1 μM, 3 μM for NF-κB DNA binding and c-Rel DNA binding, respectively. IT-901, a bioactive naphthalenethiobarbiturate derivative, has the potential for human lymphoid tumors and ameliorate graft-versus-host disease (GVHD)[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1584121-99-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-124179. | |
| Itacitinib | Itacitinib (INCB039110) is an orally active and selective inhibitor of JAK1 with an IC50 of 2 nM for human JAK1. Itacitinib shows >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2; Itacitinib is used in the research of myelofibrosis[1][2]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: INCB039110. CAS No. 1334298-90-6. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 500 mg. Product ID: HY-16997. | |
| Itacnosertib | Itacnosertib (TP-0184) is the inhibitor for FLT3, ACVR1 (ALK2, IC50=8 nM) and JAK2 (IC50=8540 nM). Itacnosertib exhibits anti-leukemic activity[1][2]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: TP-0184. CAS No. 1628870-27-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-109179. | |
| Itaconate-alkyne | Itaconate-alkyne (ITalk) is a specific bioorthogonal probe for quantitative and site-specific chemoproteomic profiling of Itaconation in living cells. Itaconate-alkyne, a functional analogue of Itaconate, exhibits comparable antiinflammatory effect with Itaconate and enables the labeling of bona fide targets of Itaconate[1]. Itaconate-alkyne is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. Uses: Scientific research. Category: Signaling pathways. Alternative Names: ITalk. CAS No. 2454181-83-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-133870. | |
| Itaconic acid | Itaconic acid, a precursor of polymers, chemicals, and fuels, can be synthesized by many fungi. Itaconic acid also is a macrophage-specific metabolite. Itaconic acid mediates crosstalk between macrophage metabolism and peritoneal tumors. Itaconic acid has anti-inflammatory, anti-microbial and immunomodulatory effect[1][2][4][5]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: Methylenesuccinic acid. CAS No. 97-65-4. Pack Sizes: 100 mg. Product ID: HY-Y0520. | |
| Itaconic acid-13C5 | Itaconic acid-13C5 is the 13C labeled Itaconic acid. Itaconic acid, a precursor of polymers, chemicals, and fuels, can be synthesized by many fungi. Itaconic acid also is a macrophage-specific metabolite. Itaconic acid mediates crosstalk between macrophage metabolism and peritoneal tumors[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2095777-38-9. Pack Sizes: 50 μg. Product ID: HY-Y0520S. | |
| Itaconic acid (Standard) | Itaconic acid (Standard) is the analytical standard of Itaconic acid. This product is intended for research and analytical applications. Itaconic acid, a precursor of polymers, chemicals, and fuels, can be synthesized by many fungi. Itaconic acid also is a macrophage-specific metabolite. Itaconic acid mediates crosstalk between macrophage metabolism and peritoneal tumors. Itaconic acid has anti-inflammatory, anti-microbial and immunomodulatory effect[1][2][4][5]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: Methylenesuccinic acid (Standard). CAS No. 97-65-4. Pack Sizes: 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-Y0520R. | |
| ITD-1 | ITD-1 is the first selective TGFβ receptor inhibitor with an IC50 of 460 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 1099644-42-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-12704. | |
| ITE | ITE is a potent endogenous agonist of aryl hydrocarbon receptor (AhR), binding directly to AHR, with a Ki of 3 nM. ITE also has immunosuppressive activity. Uses: Scientific research. Category: Signaling pathways. CAS No. 448906-42-1. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19317. | |
| Itepekimab | Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD)[1][2][3][4]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: REGN-3500; SAR-440340. CAS No. 2226742-52-3. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99673. | |
| ITH12575 | ITH12575, a CGP37157 derivative, is a potent and selective mNCX blocker. ITH12575 reduces Ca2+ influx through CALHM1 at low micromolar concentrations[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1802013-08-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-117073. | |
| ITI-214 | ITI-214 is a potent, CNS-active, orally bioavailable PDE1 inhibitor (Ki of 58 pM) with excellent selectivity against other PDE family members and against a panel of enzymes, receptors, transporters and ion channels. ITI-214 inhibits recombinant full-length human PDE1A, PDE1B and PDE1C with Kis of 33 pM, 380 pM and 35 pM, respectively. ITI-214 shows efficacy in various animal models of motor and cognitive functions[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1642303-38-5. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-12501A. | |
| Itolizumab | Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19[1][2][3]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: Anti-Human CD6 Recombinant Antibody. CAS No. 1116433-11-4. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99252. | |
| Itraconazole | Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC50 of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects. Itraconazole is a oxysterol-binding protein (OSBP) inhibitor[1][2][3][4]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: R51211. CAS No. 84625-61-6. Pack Sizes: 100 mg; 500 mg. Product ID: HY-17514. | |
| ITSA-1 | ITSA-1 is an activator of histone deacetylase (HDAC), and counteract trichostatin A (TSA)-induced cell cycle arrest, histone acetylation, and transcriptional activation[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 200626-61-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100508. | |
| ITX3 | ITX3 is a specific and nontoxic inhibitor of TrioN (N-terminal GEF domain of the multidomain Trio protein) with an IC50 value of 76 μM. ITX3 can be used for the research of agent[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 347323-96-0. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-16663. | |
| ITX5061 | ITX5061 is an orally active type II non-competitive p38 MAPK inhibitor. ITX5061 increases HDL-C levels by inhibiting SR-BI activity. ITX5061 also moderately elevates ApoA-I levels. ITX5061 reduces early atherosclerotic lesions in the aortic arch of mice fed an atherogenic diet. ITX5061 can be used in the research of atherosclerosis[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1252679-52-9. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19900. | |
| IU1 | IU1 is a selective, reversible USP14 inhibitor with an IC50 of 4-5 μM. IU1 binds USP14s catalytic cleft to block deubiquitinase activity. IU1 induces calpain-dependent Tau cleavage, causes ATP deficits, reduces E1~Ub thioester levels and 26S proteasome assembly. IU1 enhances 26S proteasome chymotrypsin-like activity, modulates LC3B-dependent autophagy flux, reduces cancer cell proliferation and migration, and blocks G0/G1 to S phase cell cycle transition in follicular thyroid cancer cells. IU1 activates autophagy-lysosomal and ubiquitin-proteasome pathways, triggers apoptosis, and reduces cervical cancer cell growth. IU1 enhances degradation of proteasome substrates linked to neurodegenerative disease, accelerates oxidized protein degradation, and increases oxidative stress resistance. IU1 can be used for the research of Alzheimers disease, follicular thyroid cancer, ischemic stroke, cervical cancer, and neurodegenerative disease[1][2][3][4][5]. Uses: Scientific research. Category: Signaling pathways. CAS No. 314245-33-5. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-13817. | |
| IU1-248 | IU1-248, a derivative of IU1, is a potent and selective USP14 inhibitor with an IC50 of 0.83 μM. Uses: Scientific research. Category: Signaling pathways. CAS No. 2307472-03-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-122885. | |
| IU1-47 | IU1-47 is a potent and specific USP14 inhibitor with an IC50 of 0.6 μM. IU1-47 inhibits IsoT/USP5 with an IC50 of 20 μM. IU1-47 induces tau elimination in cultured neurons[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 670270-31-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-122243. | |
| Ivabradine-d6 hydrochloride | Ivabradine-d6 hydrochloride is the deuterium labeled Ivabradine hydrochloride. Ivabradine hydrochloride is a new If inhibitor with IC50 of 2.9 μM, and used as a pure heart rate lowering agent. Uses: Scientific research. Category: Signaling pathways. CAS No. 2070009-63-9. Pack Sizes: 1 mg; 5 mg. Product ID: HY-B0162AS. | |
| Ivabradine hydrochloride | Ivabradine hydrochloride is a potent and orally active HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits the cardiac pacemaker current (If). Ivabradine hydrochloride reduces dose-dependently heart rate without modification of blood pressure. Ivabradine hydrochloride shows anticonvulsant, anti-ischaemic and anti-anginal activity[1][2][3][4]. Uses: Scientific research. Category: Signaling pathways. CAS No. 148849-67-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 200 mg. Product ID: HY-B0162A. | |
| Ivacaftor | Ivacaftor (VX-770) is a potent and orally bioavailable CFTR potentiator, targeting G551D-CFTR and F508del-CFTR with EC50s of 100 nM and 25 nM, respectively. Uses: Scientific research. Category: Signaling pathways. Alternative Names: VX-770. CAS No. 873054-44-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-13017. | |
| Ivacaftor-d9 | Ivacaftor-d9 is a potent CFTR modulator and exhibits an EC50 value of 255 nM for CFTR potentiation in G551D/F508del HBE Cells. Ivacaftor-D9 acts as an orally active and improved deuterated Ivacaftor analog for cystic fibrosis research[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: VX-770-d9. CAS No. 1413431-07-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg. Product ID: HY-13017S. | |
| Ivachtin | Ivachtin (Caspase-3 Inhibitor VII; compound 7a) is a nonpeptide, noncompetitive and reversibl caspase-3 inhibitor with an IC50 of 23 nM. Ivachtin has modest selectivity for the remaining caspases[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: Caspase-3 Inhibitor VII. CAS No. 745046-84-8. Pack Sizes: 5 mg; 10 mg. Product ID: HY-P1095. | |
| Ivaltinostat formic | Ivaltinostat (CG-200745) formic is an orally active, potent pan-HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat formic inhibits deacetylation of histone H3 and tubulin. Ivaltinostat formic induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of MDM2 and p21 (Waf1/Cip1) proteins. Ivaltinostat formic enhances the sensitivity of Gemcitabine-resistant cells to Gemcitabine (HY-16138) and 5-Fluorouracil (5-FU; HY-90006). Ivaltinostat formic induces apoptosis and has anti-tumour effects[1][2][3]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: CG-200745 formic. CAS No. 3078712-42-9. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-16138A. | |
| Ivermectin | Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin (MK-933) is a specific inhibitor of Impα/β1-mediated nuclear import and has potent antiviral activity towards both HIV-1 and dengue virus. It is a positive allosteric effector of P2X4 and the α7 neuronal nicotinic acetylcholine receptor (nAChRs). Ivermectin also inhibits bovine herpesvirus1 (BoHV-1) replication and inhibits BoHV-1 DNA polymerase nuclear import[1][2][3][4]. Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19[5]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: MK-933; CD-5024; K-237. CAS No. 70288-86-7. Pack Sizes: 10 mM * 1 mL in DMSO; 500 mg; 1 g; 5 g. Product ID: HY-15310. | |
| Ivermectin B1a | Ivermectin B1a, a derivative of Avermectin B1a (HY-15308), is a main component of Ivermectin (HY-15310)[1]. Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19[2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 71827-03-7. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-126937. | |
| Ivicentamab | Ivicentamab (GEN-3009) is a bispecific antibody targeting CD37 with dual epitopes. Ivicentamab carries an E430G mutation in the Fc region, which efficiently promotes IgG hexamer formation on the surface of target cells. Ivicentamab provides the parental variable regions for an H429F-engineered anti-CD37 bispecific antibody, enabling it to exert complement-dependent cytotoxicity in Daudi lymphoma cells. Ivicentamab is mainly used in lymphoma-related research[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: GEN-3009. CAS No. 2364496-42-2. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99674. | |
| Ivonescimab | Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL)[1][2][3][4][5]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: AK112. CAS No. 2428381-53-5. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-P99675. | |
| Ivosidenib | Ivosidenib (AG-120) is an orally active inhibitor of isocitrate dehydrogenase 1 mutant (mIDH1) enzyme, it exhibits profound d-2-hydroxyglutatrate (2-HG) lowering in vivo. Ivosidenib (AG-120) has the potential for AML therapy due to its acceptable safety profile and clinical activity[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: AG-120. CAS No. 1448347-49-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-18767. | |
| Ivospemin | Ivospemin (SBP-101) is an antineoplastic spermine analog. Ivospemin has shown efficacy in slowing pancreatic and ovarian tumor progression in vitro and in vivo. Ivospemin shows modest induction of polyamine catabolism, but stronger repression of ornithine decarboxylase activity. Ivospemin is promising for research of cancers[1][2][3]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: SBP-101. CAS No. 748119-79-1. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-132822. | |
| Ivuxolimab | Ivuxolimab is a fully human IgG2 agonist targeting OX40 (CD134), which selectively binds to the OX40 receptor on the surface of activated CD4+ and CD8+ T cells without inducing antibody-dependent cytotoxicity. Ivuxolimab can promote T cell proliferation, survival and cytokine (such as IFN-γ, IL-2) secretion, inhibit regulatory T cell function, and enhance anti-tumor immune response. Ivuxolimab can be used in the study of melanoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, etc[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2128729-41-7. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99159. | |
| IWP-2 | IWP-2 is an inhibitor of Wnt processing and secretion with an IC50 of 27 nM. IWP-2 targets the membrane-bound O-acyltransferase porcupine (Porcn) and thus preventing a crucial Wnt ligand palmitoylation. IWP-2 is also an ATP-competitive CK1δ inhibitor with an IC50 of 40 nM for the gatekeeper mutant M82FCK1δ[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 686770-61-6. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-13912. | |
| IWP-3 | IWP-3 is an potent inhibitor of Wnt production with an IC50 of 40 nM. IWP-3 inhibits Porcupine (Porcn) function thereby blocking palmitoylation of Wnt proteins. IWP-3 inhibits CK1γ3 and CK1ε only moderately and does not inhibit CK1α[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 687561-60-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100536. | |
| IWP-4 | IWP-4 is a Wnt inhibitor with an IC50 of 25 nM. IWP-4 specifically inhibits casein kinase 1δ/ε (CK1δ/ε), with an IC50 of 1.06 μM against wild-type CK1δ, 1.02 μM against the CK1δ kinase domain, and 7.07 μM against CK1ε; it shows enhanced inhibitory activity against the M82F CK1δ mutant (IC50 = 0.14 μM). IWP-4 is applicable to research related to cancer, Alzheimer's disease (AD), and heart failure[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 686772-17-8. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-12879. | |
| IWP-O1 | IWP-O1 is a highly potent Porcupine (Porcn) inhibitor, with an EC50 of 80 pM in L-Wnt-STF cells. IWP-O1 prevents the secretion of Wnt proteins. IWP-O1 suppresses the phosphorylation of Dvl2/3 and LRP6 in HeLa cells[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2074607-48-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100853. | |
| IWR-1 | IWR-1 (IWR-1-endo) is a tankyrase inhibitor targeting Wnt/β-catenin (IC50 = 180 nM). IWR-1 compromises critical steps of the canonical Wnt signaling, namely translocation of β-catenin to the nucleus and subsequent TCF/LEF activation and expression of Wnt/β-catenin downstream targets. IWR-1 promotes β-catenin phosphorylation by promoting stability of Axin-scaffolded destruction complexes. IWR-1 can be studied in research for anti-tumor purposes, and diseases such as osteosarcoma, colorectal cancer and psoriasis[1][2][4]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: endo-IWR 1; IWR-1-endo. CAS No. 1127442-82-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-12238. | |
| IXA4 | IXA4 is a highly selective, non-toxic IRE1/XBP1s activator. IXA4 activates IRE1/XBP1s signaling without globally activating the unfolded protein response (UPR) or other stress-responsive signaling pathways (e.g., the heat shock response or oxidative stress response). IXA4 reduces secretion of APP through IRE1 activation[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1185329-96-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-139214. | |
| IXA6 | IXA6 is a novel IRE1/XBP1s activator, and can induce IRE1 RNase activity[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1021106-40-0. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg. Product ID: HY-139212. | |
| IXA62 | IXA62 is an orally active and selective IRE1/XBP1s activator (EC50 = 0.31 μM) that reduces Aβ secretion. IXA62 enhances glucose-stimulated insulin secretion from rat insulinoma cells[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 956783-34-9. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-176040. | |
| Ixabepilone | Ixabepilone (BMS-247550) is an orally bioavailable microtubule inhibitor, which binds to tubulin and promotes tubulin polymerization and microtubule stabilization, thereby arrests cells in the G2-M phase of the cell cycle and induces tumor cell apoptosis. Uses: Scientific research. Category: Signaling pathways. Alternative Names: BMS-247550; Aza-epothilone B. CAS No. 219989-84-1. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg. Product ID: HY-10222. | |
| Ixazomib | Ixazomib (MLN2238) is a selective, potent, and reversible proteasome inhibitor, which inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with an IC50 of 3.4 nM (Ki of 0.93 nM). Uses: Scientific research. Category: Signaling pathways. Alternative Names: MLN2238. CAS No. 1072833-77-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-10453. | |
| Ixazomib citrate | Ixazomib citrate (MLN9708) is a selective, orally active, second-generation proteasome inhibitor. Ixazomib citrate can be used for the study of a broad range of human malignancies[1][2][3]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: MLN9708. CAS No. 1239908-20-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 250 mg; 500 mg. Product ID: HY-10452. | |
| Ixekizumab | Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis[1][2]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: LY2439821. CAS No. 1143503-69-8. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-P9924. | |
| Ixotatug | Ixotatug is a monoclonal antibody targeting human CLDN6 (claudin-6). Ixotatug specifically binds to CLDN6, interfering with relevant signaling pathways in tumor cells and exerting antitumor activity. Ixotatug is promising for research of cancers[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: TORL-1-23 Antibody. CAS No. 3018936-99-4. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P991143. | |
| Izalontamab | Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3 monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: SI-B001; BL-B01D1 Antibody. CAS No. 2559704-24-2. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99676. | |
| Izastobart | Izastobart is an anti-C5AR1 human IgG1 λ2 monoclonal antibody[1]. Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096). Uses: Scientific research. Category: Signaling pathways. Alternative Names: HIB210; MOR044254; MOR210; TJ-210; TJ-210001; WBP2191. CAS No. 2769937-42-8. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P990745. | |
| Izeltabart | Izeltabart (MGA021) is a humanized IgG1 monoclonal antibody targeting ADAM9, which can be used as an ADC Antibody to synthesize the ADC molecule IMGC936 (Izeltabart Tapatansine). Izeltabart can be used in the study of cancer[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: IMGC-936 antibody; MGA021. CAS No. 2642078-60-0. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P990027. | |
| Izencitinib | Izencitinib (TD-1473) is an orally active, non-selective and gut-restricted JAK inhibitor. Izencitinib (TD-1473) can be used in the study for ulcerative colitis[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: TD-1473; JNJ-8398. CAS No. 2051918-33-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-109148. | |
| Izenivetmab | Izenivetmab (ZTS-00075623) is an anti-NGFB IgG2κ monoclonal antibody. Izenivetmab shows anti-inflammatory and analgesic effects by targeting anti-nerve growth factor (NGF). Izenivetmab can be used for the research of osteoarthritis[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: ZTS-00075623. CAS No. 2447755-72-6. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99677. | |
| iZMYND8-34 | iZMYND8-34 is a ZMYND8 inhibitor with an IC50 of 0.66 μM. iZMYND8-34 inhibits the binding of H3K4me1-H3K14ac peptide to the ZMYND8 protein. iZMYND8-34 inhibits ZMYND8s histone recognition. iZMYND8-34 blocks neuroendocrine prostate cancer development[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1358901-59-3. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-403538. | |
| Izorlisib | Izorlisib (CH5132799) is a selective class I PI3K inhibitor. Izorlisib inhibits class I PI3Ks, particularly PI3Kα, with an IC50 of 14 nM. Uses: Scientific research. Category: Signaling pathways. Alternative Names: CH5132799. CAS No. 1007207-67-1. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15466. | |
| Izumerogant | Izumerogant (IMU-935) is an orally active RORγ/DHODH dual inhibitor with IC50s of 10 and 98 nM against RORγ and DHODH. Izumerogant efficiently blocks the replication of SARS-CoV-2, HCMV and HAdV5 with EC50 values between 3.6 and 17 nM. Izumerogant can be used for researching antiviral properties[1][2]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: IMU-935. CAS No. 2299252-72-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-152851. | |
| J10-1 | J10-1 is a hapten small molecule. J10-1 accelerates peptide exchange in MHC class II molecules in an HLA-DM-independent manner, and its effect is not affected by the polymorphism of the P1 pocket of MHC class II molecules. J10-1 enhances the processes of peptide dissociation, peptide binding and peptide association of MHC class II molecules on the surface of B cells. J10-1 can be used for research on immunoregulation[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1069110-72-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-157269. | |
| (±)-J-113397 | (±)-J-113397 is a potent and selective non-peptidyl ORL1 receptor antagonist with a Ki of 1.8 nM for cloned human ORL1. J-113397 inhibited nociceptin/orphanin FQ-stimulated GTPγS binding to CHO cells expressing ORL1 with an IC50 value of 5.3 nM. J-113397 can be used for researching the physiological roles of nociceptin/orphanin FQ[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 217461-40-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-107721. | |
| J-113863 | J-113863 is a potent and selective CCR1 antagonist with IC50 values of 0.9 nM and 5.8?nM for human and mouse CCR1 receptors, respectively. J-113863 is also a potent antagonist of the human CCR3 (IC50 of 0.58 nM) , but a weak antagonist of the mouse CCR3 (IC50 of 460 nM). J-113863 is inactive against CCR2, CCR4 and CCR5, as well as the LTB4 or TNF-α receptors. Anti-inflammatory effect[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 353791-85-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-103360. | |
| J14 | J14 is a reversible sulfiredoxin inhibitor with an IC50 of 8.1 μM. J14 induces oxidative stress (intracellular ROS accumulation) by inhibiting sulfiredoxin, leading to cytotoxicity and cancer cell death[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1043854-13-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-135008. | |
| J-2156 | J-2156 is a high potent, selective somatostatin receptor type 4 (SST4 receptor) agonist with IC50s of 0.05 nM and 0.07 nM for human and rat SST4 receptors, respectively. J-2156 is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 848647-56-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-111615. | |
| J-2156 TFA | J-2156 TFA is a high potent, selective somatostatin receptor type 4 (SST4 receptor) agonist with IC50s of 0.05 nM and 0.07 nM for human and rat SST4 receptors, respectively. J-2156 TFA has anti-inflammatory activity and it is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2387505-73-7. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-111615A. | |
| J9Z38 | J9Z38 is a metabolite of Cyantraniliprole (HY-12779), a broad-spectrum agrochemical insecticide belonging to the anthranilic diamide insecticide class. Cyantraniliprole effectively controls the growth of various pests on fruits, vegetables, cereals and other crops. Thus, J9Z38 is a key indicator for indirect detection and evaluation of Cyantraniliprole residue levels[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1414864-34-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-160758. | |
| JA2 | JA2 is an inhibitor of metalloendopeptidase 24.15 that can potentiate the hypotensive response to bradykinin in rat[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 277333-45-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg. Product ID: HY-164704. | |
Would you like to list your products on USA Chemical Suppliers?
Our database is helping our users find suppliers everyday.